第3期随机化COMMODORE 2试验:克罗瓦利马布与埃奎利祖马布在患有阳性夜间血红蛋白尿症的患者中,无需补充抑制
Alexander Röth1, Guangsheng He2, Hongyan Tong3
1Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
American journal of hematology
|June 17, 2024
概括
克罗瓦利马布在治疗阳性夜间血红蛋白尿症方面表现出与埃库利祖马布的非劣势,在血液溶解控制和输血避免方面表现出相似的疗效. 这种新型的C5补充抑制剂提供了一个方便的自我管理选项,具有类似的安全性.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 透性夜间血红蛋白尿 (PNH) 是一种罕见的,获得的血液疾病,其特征是补充介导的血液溶解.
- 目前的治疗方法往往涉及C5补充抑制剂,但需要新的选择来改善管理和疗效.
研究的目的:
- 评估与eculizumab相比,crovalimab在没有使用C5抑制剂的PNH成年患者中的非劣势性.
- 评估关键的疗效终点,包括血液溶解控制,避免输血和患者报告的疲劳.
主要方法:
- 随机的,开放的,多中心的COMMODORE 2试验 (NCT04434092) 招募了204名未使用C5抑制剂的PNH患者.
- 患者被随机分为2:1接受皮下克罗瓦利马布或静脉注射eculizumab,持续24周.
- 同一主要终点是患者实现血解控制 (LDH ≤1.5 × ULN) 和避免输血的比例.
主要成果:
- 克罗瓦利马布在血液溶解控制 (79.3% vs. 79.0%) 和输血避免 (65.7% vs. 68.1%) 方面与埃库利祖马布无差.
- 二级终点,包括突破性血液溶解和血红蛋白稳定,也显示了两种治疗方法之间的可比结果.
- 患者在两种疗法中都报告了临床上有意义的疲劳改善 (FACIT-Fatigue得分),并且在切换时通常更喜欢covalimab.
结论:
- 克罗瓦利马布是C5抑制剂原始PNH患者的eculizumab的非劣质替代品,在皮下自给药时提供持续的C5抑制.
- 该研究强调了covalimab的积极益处风险概况,相似的安全性和患者偏好,支持其在PNH管理中的作用.
相关概念视频
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...


